Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will sponsor tennis players participating in The Championships, Wimbledon 2024 to spotlight its advanced...
Compact, single-use, and simple-to-use technology offers surgeons a fast, reliable navigation solution for hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company,...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the review of medical technologies guidance from the UK National Institute for Health and Care Excellence (NICE)...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC “ the world's premier mixed martial...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces full commercial availability of its AETOS Shoulder System in the US, along with 510(k) clearance for its use...
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL—Š AGILI-C—Š Cartilage Repair Implant alongside the...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a new report examining musculoskeletal injury care and reimbursement in Australia that urges health payers and providers to resolve system-wide challenges hindering positive patient pathways from primary settings through to recovery.
New study confirms Smith+Nephew™s REGENETEN Bioinductive Implant reduces full-thickness rotator cuff re-tear rates¹ by 68%
Nov 2 (Reuters) - British medical products maker Smith+Nephew (SN.L) said weight-loss drugs could help previously ineligible overweight patients get approval for joint replacement surgery, playing down concerns about the impact of the new therapies on its business.